Stock Scorecard



Stock Summary for United Therapeutics Corp (UTHR) - $306.97 as of 3/28/2025 9:16:06 PM EST

Total Score

20 out of 30

Safety Score

67 out of 100

Currently on the following lists
Growth Stock List
Tim's Recommendation
Buy

Growth List Algorithm Criteria for UTHR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for UTHR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for UTHR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for UTHR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for UTHR (67 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for UTHR

United Therapeutics ( UTHR ) Down 4.8% Since Last Earnings Report: Can It Rebound? 3/28/2025 3:30:00 PM
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ ( treprostinil ) Inhalation Powder - Liquidia ( NASDAQ:LQDA ) 3/28/2025 1:30:00 PM
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ ( treprostinil ) Inhalation Powder 3/28/2025 1:30:00 PM
3d Systems ( DDD ) Q4 2024 Earnings Call Transcript 3/27/2025 7:00:00 PM
3D Systems Reports Fourth Quarter and Full Year 2024 Financial Results 3/26/2025 8:15:00 PM
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update 3/19/2025 10:30:00 AM
MannKind ( MNKD ) Q4 2024 Earnings Call Transcript 2/27/2025 5:30:00 AM
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat 2/26/2025 3:56:00 PM
United Therapeutics ( UTHR ) Surpasses Q4 Earnings and Revenue Estimates 2/26/2025 12:35:00 PM
Seeking Clues to United Therapeutics ( UTHR ) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics 2/24/2025 2:16:00 PM

Financial Details for UTHR

Company Overview

Ticker UTHR
Company Name United Therapeutics Corp
Country USA
Description United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/29/2025

Stock Price History

Last Day Price 306.97
Price 4 Years Ago 216.08
Last Day Price Updated 3/28/2025 9:16:06 PM EST
Last Day Volume 223,153
Average Daily Volume 568,642
52-Week High 417.81
52-Week Low 221.53
Last Price to 52 Week Low 38.57%

Valuation Measures

Trailing PE 12.61
Industry PE 37.01
Sector PE 40.10
5-Year Average PE 15.72
Free Cash Flow Ratio 4.11
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 4.58
Total Cash Per Share 74.60
Book Value Per Share Most Recent Quarter 143.74
Price to Book Ratio 2.17
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 4.85
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 44,912,200
Market Capitalization 13,786,698,034
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 6.35%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 42.10%
Annual Earnings Growth 35.40%
Reported EPS 12 Trailing Months 24.43
Reported EPS Past Year 24.60
Reported EPS Prior Year 19.84
Net Income Twelve Trailing Months 1,110,900,000
Net Income Past Year 984,800,000
Net Income Prior Year 727,300,000
Quarterly Revenue Growth YOY 19.70%
5-Year Revenue Growth 6.86%
Operating Margin Twelve Trailing Months 49.20%

Balance Sheet

Total Cash Most Recent Quarter 3,350,500,000
Total Cash Past Year 3,009,000,000
Total Cash Prior Year 2,869,400,000
Net Cash Position Most Recent Quarter 2,950,500,000
Net Cash Position Past Year 2,309,000,000
Long Term Debt Past Year 700,000,000
Long Term Debt Prior Year 800,000,000
Total Debt Most Recent Quarter 400,000,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.94
Total Stockholder Equity Past Year 5,984,800,000
Total Stockholder Equity Prior Year 4,796,700,000
Total Stockholder Equity Most Recent Quarter 6,100,900,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 898,100,000
Free Cash Flow Per Share Twelve Trailing Months 20.00
Free Cash Flow Past Year 747,600,000
Free Cash Flow Prior Year 663,700,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -7.62
MACD Signal -9.39
20-Day Bollinger Lower Band 304.79
20-Day Bollinger Middle Band 350.12
20-Day Bollinger Upper Band 395.46
Beta 0.64
RSI 40.70
50-Day SMA 331.04
150-Day SMA 265.04
200-Day SMA 246.80

System

Modified 3/28/2025 10:09:14 AM EST